GlobeNewswire by notified

Biotalys’ first biocontrol Evoca™ demonstrated to be an excellent new tool for    growers in 2021 independent field trials


Ghent, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pressrelease

Biotalys’firstbiocontrolEvoca™demonstratedtobean excellentnewtoolforgrowersin2021independentfieldtrials

Evoca™showntobe anidealpartnerinintegratedpestmanagement programs

Ghent, BELGIUM and Research Triangle Park (NC), UNITED STATES – 15 November 2021,07:00 CET Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions, today announced the strong performance of its first protein-based biofungicide Evoca™* in independent efficacy field trials conducted by a number of highly reputed public institutes in 2021.

Evoca™ is aimed at providing fruit and vegetable growers with a new rotation partner in integrated pest management programs to help control devastating fungal diseases such as Botrytis and powdery mildew, reducing dependency on chemical pesticides and corresponding residues in harvested produce and offering a distinctive new tool to manage pathogen resistance development.

The extension trials for grapes and strawberries, conducted by a number of prestigious independent academic institutions in the United States, are industry gold-standard studies which provide growers and crop advisors with detailed information on the performance of existing and pipeline crop protection products. In all of the trials conducted in 2021, the final commercial formulation of Evoca™ was tested among many other treatments and non-treated control plots, enabling the comparison of its performance with conventional chemical and biological fungicide products. Full results of these trials are being made public by the respective institutions.

Luc Maertens, COO of Biotalys, said: “The outcomes of this year’s independent field trials show that Evoca™ consistently performs as well as established market leaders when used in integrated pest management programmes, further validating our novel approach and technology. We believe that Evoca™, as a fully-biodegradable, protein-based product, has great potential as a partner for rotation that is safe and easy to use, offering a new modality to protect against resistance and reduce environmental impact while maintaining crop yields.”

These independent trials represent one element of Biotalys’ broader testing programme ahead of the planned market calibration launch of Evoca™, starting in the United States in late 2022 – pending regulatory approval. Biotalys’ ongoing global fruit and vegetable trial program has now reached over 450 trials across multiple regions, pathogens and crops, providing data essential for both regulatory and product development and positioning purposes, as well as the development of next products.

Biotalys submitted Evoca™ for registration to the Environmental Protection Agency (EPA) in the United States in December 2020 and expects to receive EPA approval in H2 2022. Biotalys also submitted for approval in California in April 2021, as this State performs its own in-depth review. In the European Union, Biotalys received confirmation from the European Food Safety Authority (EFSA) and the College for approval of crop protection products and biocides (Ctgb) that the registration dossier submitted in March 2021 for the active substance of Evoca™ is admissible for review.


In all the studies referred to below, Evoca™ was identified as EXP14 to guarantee unbiased results. For each trial, a link is added to where the results of the relevant study were published.

A.   UniversityofCaliforniaDavis(PrimaryInvestigatorDr.AkifEskalen)2021grapevinetrials


Across a total of 38 different treatment programs, three entries compared Evoca™ to synthetic and some biological fungicides in prevention of BFR. Treatments were applied three times throughout the trial (bloom, pre-closure, and version). Evoca™ treatments were mixed with adjuvants but not mixed or rotated with any other fungicides.

Evoca™, applied with an adjuvant, had the second lowest mean disease incidence of Botrytis of all the treatments, and all three Evoca™ treatments performed better than the un-treated control.

To view this piece of content from, please give your consent at the top of this page.To view this piece of content from, please give your consent at the top of this page.

Untreated                                      Treated with Evoca™ mixed with an adjuvant


Evoca™ was included in three treatment entries across a total of 65 treatment programs in this trial. Evoca™ at the label recommended rate was mixed with the same adjuvants as in the Botrytis trial and rotated with sprayable sulfur that is efficacious against powdery mildew.

Treatments were applied once a week, swapping between sprayable sulfur and Evoca™. In all three Evoca™ treatment entries no powdery mildew was observed.

To view this piece of content from, please give your consent at the top of this page.To view this piece of content from, please give your consent at the top of this page.
Untreated                                              Treated with Evoca™ mixed with an adjuvant and rotated with a sprayable sulfur

B.  UniversityofFlorida(PrimaryInvestigator,Dr.NataliaPeres)2020/2021strawberrytrials

Botrytisfruitrot(BFR) (

Evoca™ was assessed in six treatments across this study. Treatments included rotations of Evoca™ at two doses with two synthetic fungicides.

The rotations of Evoca™ with the synthetic fungicides provided disease incidence levels equivalent to other synthetic only rotations and improved yields drastically over the untreated controls.

Powderymildew (

Biotalys entered six treatments into this study. Four treatments included rotations of Evoca™ with two synthetic fungicides.

The rotations of Evoca™ with synthetic materials provided disease incidence levels equivalent to other synthetic-only rotations and improved yields and disease reduction drastically over the untreated controls.

C.   CaliforniaPolytechnicStateUniversitySanLuisObispo,StrawberryCenter(PrimaryInvestigator,KyleBlaur& Dr.GeraldHolmes)2021strawberry trials

( and

Evoca™ was tested in rotation alone, and with adjuvants in a total of five different application combinations. Post-harvest incubation of fruit occurred at ambient temperature, with assessments taken 6 days after harvest.

Evoca™, alternating with one synthetic fungicide, showed incidence of BFR which was statistically significantly lower than in the non-treated control plots, and among the top five lowest disease incidence treatments.

D.   UniversityofCaliforniaDavisCooperativeExtension(PrimaryInvestigator,Dr.SurendraDara)


Botrytisfruitrot(BFR) (

Evoca™ was included in two treatment entries across a total of 25 treatment programs overall and was compared to both synthetic and some biological fungicides.

By the conclusion of the trial none of the treatments – including full synthetic programs – showed statistically significant improvement over the untreated control after the fourth spray application or for the average of four applications during the trial, leading to less conclusive results for all products tested on the basis of this trial.

States,the EuropeanUnion orelsewhere and isnotbeing offeredforsale.

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on

To view this piece of content from, please give your consent at the top of this page.

Toon Musschoot, Head of Investor Relations & Communications T: +32 (0)9 274 54 00


This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

For press release in Dutch, please click HERE

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate5.12.2021 18:21:41 CET | Press release

Bavarian Nordic’s non-adjuvanted COVID-19 vaccine candidate, ABNCoV2 (100μg), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodiesThe large boosting effect of ABNCoV2 elevated the neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21A similar fold increase was observed for all SARS-CoV-2 variants tested (Wuhan, Alpha, Beta and Delta) following the booster vaccination with ABNCoV2The vaccine was well-tolerated, with no serious adverse events reportedThese initial results confirm the potential of ABNCoV2 to function as a universal COVID-19 booster vaccineThe Company’s management will host a conference call tomorrow at 2 pm CET (8 am EST) to discuss the results COPENHAGEN, Denmark, December 5, 2021 – Bavarian Nordic A/S (OMX: BAVA), a fully integrated vaccines company, announced today positive topline results f

Bavarian Nordic rapporterer positive toplinjeresultater fra fase 2-forsøg med sin COVID-19 vaccinekandidat5.12.2021 18:21:41 CET | pressemeddelelse

Bavarian Nordics COVID-19 vaccinekandidat uden hjælpestof (adjuvant), ABNCoV2 (100μg), demonstrerede i et fase 2 forsøg en solid boostereffekt, ved at forhøje de eksisterende niveauer af SARS-CoV-2 neutraliserende antistoffer mod Wuhan varianten 2-40 gange afhængigt af de initiale antistofniveauerDen høje boostereffekt af ABNCoV2 forhøjede niveauet af neutraliserende antistoffer til niveauer som er blevet rapporterede som værende yderst effektive (>90%) mod SARS-CoV-21En lignende forhøjelse blev observeret for alle testede SARS-CoV-2 varianter (Wuhan, Alpha, Beta og Delta) efter boostervaccination med ABNCoV2Vaccinen var veltolereret med ingen rapporterede alvorlige bivirkningerDisse toplinjeresultater bekræfter ABNCoV2’s potentiale til at fungere som en universel COVID-19 boostervaccineVirksomhedens ledelse vil afholde en telefonkonference i morgen kl. 14:00 CET for at diskutere resultaterne KØBENHAVN, Danmark, 5. december 2021 – Bavarian Nordic A/S (OMX: BAVA), et fuldt integreret va

Galapagos increases share capital through subscription right exercises3.12.2021 22:01:00 CET | Press release

Mechelen, Belgium; 3 December 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 22,600 new ordinary shares on 3 December 2021, for a total capital increase (including issuance premium) of €578,700.00. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one management board member exercised 5,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €354,582,005.11, the total number of securities conferring voting rights amounts to 65,552,721, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and al

Sampo plc’s share buybacks 03/12/20213.12.2021 21:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 03/12/2021 at 10:30 pm Sampo plc’s share buybacks 03/12/2021 On 03/12/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)23,68743.29AQEU27,42643.28CEUX4,32043.37TQEX72,59243.31XHELTOTAL128,02543.30 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 6,263,553 Sampo A shares representing 1.13 per cent of the total number of shares in Sampo plc. Detail

Projekt Öyfjellet försenat – beräknas färdigställas under första kvartalet 20223.12.2021 21:15:00 CET | Pressemelding

Hässleholm den 3 december 2021 I delårsrapporten för det tredje kvartalet, som offentliggjordes den 18 november 2021, kommunicerade Eolus att det finns risk för försening i färdigställandet av det norska 400 MW projektet Öyfjellet. Baserat på uppdaterad information om byggprocessen beräknar Eolus nu att vindparken färdigställs under det första kvartalet 2022. Per idag, den 3 december 2021, har samtliga 72 turbiner färdigmonterats. 34 turbiner har börjat generera el. Huvudskälen till förseningen är utmanande väderförhållanden, vilket har påverkat installationsarbetet, samt Covid-19 relaterade orsaker som begränsat både resemöjligheterna för personal och lett till leveransförseningar avseende komponenter. Förseningen kommer att ha en negativ påverkan på Eolus projektmarginal. För ytterligare information kontakta: Per Witalisson, VD, telefon +46 (0)70-265 16 15 Johan Hammarqvist, kommunikationschef, telefon +46 (0)720-50 59 11 Kort om Eolus Eolus Vind är en av Nordens ledande projektörer

Project Øyfjellet delayed - new estimated completion in the first quarter of 20223.12.2021 21:15:00 CET | Press release

Hässleholm, Sweden, December 3rd, 2021 In the interim report for the third quarter, released on November 18, 2021, Eolus communicated a risk of delay in the completion of the 400 MW Norwegian wind project Øyfjellet. Based on updated information of the construction progress, Eolus now estimates that the wind farm will be completed during the first quarter of 2022. As of today, December 3, 2021, construction of all 72 turbines have been completed. First electricity production has been achieved by 34 turbines. The main reasons for the delay are challenging weather conditions which has effected the progress of the installations and Covid-19 related issues which has restricted both travel possibilities for personnel and led to delays in delivery of components. The delay is expected to have a negative impact on Eolus’ profit margin for the construction of the project. For further information contact: Per Witalisson, CEO, +46 70-265 16 15 Johan Hammarqvist, Head of Communications, +46 720 50

ING reports outcome of 2021 EU-wide Transparency Exercise and Risk Assessment Report3.12.2021 18:12:26 CET | Press release

ING reports outcome of 2021 EU-wide Transparency Exercise and Risk Assessment Report ING notes the announcements made today by the European Banking Authority (EBA) and the European Central Bank (ECB) regarding the information of the 2021 EU-wide Transparency Exercise and Risk Assessment Report. Background EU‐wide Transparency Exercise The EBA Board of Supervisors approved the package for the EU‐wide Transparency Exercise, which since 2016 is performed on an annual basis and published along with the Risk Assessment Report (RAR). The annual transparency exercise is based solely on regulatory reporting data (COREP/FINREP) on the form and scope to assure a sufficient and appropriate level of information to market participants. The templates were centrally filled in by the EBA and sent afterwards for verification by banks and supervisors. The outcome of the exercise related to ING Group can be found in the annexes on the EBA website. Note for editors For further information on ING, please v